Zimmer Partners LP Makes New Investment in Roivant Sciences Ltd. (NASDAQ:ROIV)

Zimmer Partners LP bought a new stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 252,900 shares of the company’s stock, valued at approximately $2,992,000.

A number of other large investors have also bought and sold shares of the company. Vestal Point Capital LP bought a new position in Roivant Sciences during the fourth quarter worth about $14,788,000. Vident Advisory LLC boosted its stake in Roivant Sciences by 98.7% in the fourth quarter. Vident Advisory LLC now owns 32,039 shares of the company’s stock worth $379,000 after buying an additional 15,918 shares in the last quarter. Tyro Capital Management LLC grew its position in Roivant Sciences by 20.1% during the fourth quarter. Tyro Capital Management LLC now owns 2,108,283 shares of the company’s stock valued at $24,941,000 after acquiring an additional 353,307 shares during the last quarter. Rafferty Asset Management LLC grew its position in Roivant Sciences by 8.4% during the fourth quarter. Rafferty Asset Management LLC now owns 722,429 shares of the company’s stock valued at $8,546,000 after acquiring an additional 55,960 shares during the last quarter. Finally, Patient Square Capital LP raised its stake in shares of Roivant Sciences by 2.1% during the fourth quarter. Patient Square Capital LP now owns 12,480,000 shares of the company’s stock worth $147,638,000 after acquiring an additional 251,535 shares in the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.

Roivant Sciences Stock Performance

Shares of ROIV stock opened at $11.04 on Wednesday. The company has a market capitalization of $7.88 billion, a P/E ratio of -73.60 and a beta of 1.23. Roivant Sciences Ltd. has a fifty-two week low of $8.73 and a fifty-two week high of $13.06. The stock has a 50 day moving average price of $10.52 and a two-hundred day moving average price of $11.07.

Insider Transactions at Roivant Sciences

In related news, COO Eric Venker sold 100,000 shares of the firm’s stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $10.22, for a total value of $1,022,000.00. Following the sale, the chief operating officer now directly owns 1,116,345 shares of the company’s stock, valued at $11,409,045.90. This trade represents a 8.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Vivek Ramaswamy sold 273,959 shares of the business’s stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $11.47, for a total value of $3,142,309.73. Following the transaction, the insider now owns 39,799,611 shares in the company, valued at approximately $456,501,538.17. This represents a 0.68% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,223,959 shares of company stock worth $13,420,035. Insiders own 7.90% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on ROIV shares. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a research note on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a research note on Monday, April 21st.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.